Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion type Assertion NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_head.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion wasGeneratedBy ECO_0000203 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion wasDerivedFrom befree-20150227 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion SIO_000772 23801497 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion evidence source_evidence_literature NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.